Information Provided By: 
Fly News Breaks for March 24, 2016
INSY
Mar 24, 2016 | 06:51 EDT
After hosting senior management in meetings with investors, Piper Jaffray analyst David Amsellem reiterates an Overweight rating on Insys Therapeutics with a $46 price target. The extension of the FDA action date for the Syndros new drug application is related to scheduling, Amsellem tells investors in a research note. Insys made it clear that abandoning certain managed care contracts, thus sacrificing some prescription volumes, may actually be beneficial to Subsys net sales, the analyst points out.
News For INSY From the Last 2 Days
There are no results for your query INSY
